Metagenomi price target lowered to $11 from $12 at Chardan
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
5 days ago
- Business Insider
Metagenomi price target lowered to $11 from $12 at Chardan
Chardan lowered the firm's price target on Metagenomi (MGX) to $11 from $12. The firm updated its model for Q2 financials and takes a slightly more conservative stance on programs/platform beyond hem A and the Ionis collaboration in light of the company's increasing focus on pipeline execution and advancing gene editing platform competition. The firm noted its Q2 adjustments shift its price target lower. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Business Insider
5 days ago
- Business Insider
Lexeo Therapeutics price target lowered to $15 from $20 at Chardan
Chardan lowered the firm's price target on Lexeo Therapeutics (LXEO) to $15 from $20 and keeps a Buy rating on the shares after the company reported Q2 results and affirmed upcoming catalysts for its LX2006 and LX2020 programs. The firm said it awaits further visibility on focus and strategy, but thinks a non-viral approach could be 'quite interesting.' Chardan added that it updated its Lexeo model for Q2 financials, including dilution from the May offering. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Business Insider
6 days ago
- Business Insider
Palvella Therapeutics price target raised to $60 from $50 at Chardan
Chardan raised the firm's price target on Palvella Therapeutics (PVLA) to $60 from $50 and keeps a Buy rating on the shares. The firm updates its model after the company's Q2 results and affirmed timelines on four upcoming catalysts including Q4 data from the Phase 2 TOIVA trial in cutaneous venous malformations, Q1 of 2026 data from the Phase 3 SELVA trial in microcystic lymphatic malformations, disclosure of a 3rd indication for QTORIN rapamycin and a 2nd QTORIN platform candidate before 2025-end, the analyst tells investors in a research note. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
